缺血性卒中和短暂性脑缺血发作的二级预防

缺血性卒中和短暂性脑缺血发作的二级预防

TIA 160 140 120 100 80 60 135

150 76.1 40 20 0 3 Stroke. 2006;37:63-68 World Health Organization. Atlas of Heart Disease and Stroke. http://www.who.int/cardiovascular_diseases/resources/atlas/en/

/10 200 165 200 150 100 50 165 77 51

0 3 n=1091 8.8 13.0 58.5 56.0

13.0 16.3 22.0 17.9 29.0 41.5 /TIATIA 20.0 16.9

21.0 0.0 10.0 20.0 30.0 40.0

50.0 60.0 70.0

TIA TIA 10mmHg, 49% 5mmHg, 46% TIA 7 RCT

TIA 140/TIA90mmHg 130/TIA80mmHg

1. 2. 3. 1mmol/TIAL 25% : 1. 2.

LDL-C LDL VLDL 1 2 /TIATIA 2010 TIA - TIA

TIA CE (I) (II)II)

(II) LDL-C LDL-C <2.1mmol/TIAL 80mg/TIAdl

>2.1mmol/L 80mg/dl >2.6mmol/L 100mg/dl SPARCL >40% <2.6mmol/TIAL 100mg/TIAdl

30-40% . 2008;47(10) CEA TIA - TIA

TIA CE (I) (II)II) (II)

LDL-C LDL-C <2.1mmol/TIAL 80mg/TIAdl >2.1mmol/L 80mg/dl

>2.6mmol/L 100mg/dl >40% <2.6mmol/TIAL 100mg/TIAdl 30-40% / . . 2007;46(1):81-8 TIA

LDL-C 2.6mmol/L(100mg/dL) LDL-C 2.6mmol/L(100mg/ dL) , /TIA / / / , LDL-C 2.07mmol/L(80mg/ dL) , - TIA , LDLC<80mg/dl LDL-C 40% Yes LDL-C No

LDL-C Because 1. 20 2. LDL-C 1.8-2.1mmol/TIAL 3. 4.

1. 14 90056 CTT LDL-C 1mmol/TIAL 2. HPS : 3. TNT : LDL-C 2.7mmol/TIAL 1..7mmol/TIAL

SPARCL /TIA 4-8 612 1 3

CK CK 5 CK CK 2010

IDF 2010 34400 47200 IGT http://www.diabetesatlas.org/content/global-burden 66% n=557 , 2008, 12:824-827. :77% n 216 Ivey FM, et al. Cerebrovasc Dis 2006;22:368371.

n=25 72h MRI NIHSS mSR Baird TA, et al. Stroke 2003, 34:22082214. 286 238 P 0.001 mRS mRS 0-1 % NIHSS NIHSS

P 0.001 Matz K, et al. Diabetes Care, 2006, 29:792-797. 286 238 P<0.001 Matz K, et al. Diabetes Care, 2006, 29:792-797. HbA1c 1mmol/TIAL HR UKPDS 597 UKPDS 66 HbA1c 1mmol/L 17%

37% P=0.0071 P=0.0144 Diabetes Care,2004, 27:201207. 2 1mmol/L HR 2 38 2h 1mmol/L 17% Diabetologia. 2008 July; 51(7): 11231126.

5 HR 2 Wilterdink JL, Easto JD. Arch Neurol, 1992, 49(8):857863. OGTT : (IFG) IGT) (DM)) IGT 50% IFG IGT

mmol/ L 7.0 6.1 IFG+IGT IFG 5.6 IGT 7.8 11.1

OGTT2 mmol/L ADA IFG 5.6mmol/L 6.1mmol/L American Diabetes Association. Diabetes Care, 2010, 33:S11-S61. . 2 2007 . , 2008, 88(18):1227-1245. 2 2007 . 2 2007 . , 2008, 88(18):1227-1245. /TIA -------- REACH R: Risk factors managements E: Early detection

A: All-sides glucose control C: Combination rationality H: Hypoglycemia prevention R 1 -- 2 <130/TIA80mmHg, ACEI or ARB SPARCL R

ADA LDL-C <70mg/TIAdl 1.8mmol/TIAL LDL-C 30%-40% E /TIATIA oral glucose tolerance test OGTT IGR 1998-2001 5,628 6.87% IGR 8.53%

OGTT 49% 75% IGR IFG IFG+IGT IGT IGR J WP.Diabetologia,2007 Feb;50(2):286-292. OGTT (%)

80 100 80 60 20 0 80 60 40

3513 (%) 25 5 100 2/3 OGTT 40

OGTT OGTT 20 0 OGTT

2 European Heart Journal (2004) 25, 18801890. Da-Yi Hu, et al. European Heart Journal 2006;27:2573-2579. OGTT OGTT 89% IGR 14% n=557 IFG IGT+IFG IGT OGTT OGTT

, 2008, 12:824-827. ESC/EASD OGTT CVD OGTT B 2

OGTT A European Heart Journal .2007 (28):88136. WHO/IDF OGTT OGTT IGT FPG 6.1-6.9mmol/Lmmol/L OGTT

Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation OGTT 0 30 60 120 180 1985 WHO OGTT 75g 2 World Health Organ Tech Rep Ser. 1985;727:1-113.

A HbA1c 1. 3 2. 3. HbA1c6.5%6.5% 2004 woerle 64% HbA1c<7% 94% HbA1c HbA1c C 1. 2.a-

3. 4.- 5. H 2.8mmol/Lmmol/L 3.9mmol/Lmmol/L 1. 2. 3. /TIA /TIA /TIA /TIA /TIA

TIA FPG FPG 7mmol/TIAL OGTT / /TIA 10mmom/ L 10mmom/L

8.3mmom/L FPG 7.0mmom/L 7.0mmom/L* OGTT + IGT

IFG * 2010 /TIA 2 50-325mg/TIAd 25mg 200mgbid

75mg/TIAd 75mg/TIAd 50-325mg/TIAd I A I A ADP GPIIb/TIAIIIa

- 2010 Lancet 13% ASA 1.Hankey GJ,et al. Lancet Neurol,2010; 9: 27384

24 RR 95 CI 0.75 (0.71-0.81) 25 0.62 (0.55-0.71) 38

0.62 (0.51-0.75) 38 0.62 (0.48-0.80) 38 0 2007 24 2004 0.5 1

79439 30 55 24 Long-term Aspirin Use and Mortality in Women ARCH INTERN MED/VOL 167, MAR 26, 2007 562 /TIA 1000 0 2 4 6

8 10 12 14 16 55,462 108 273mg/TIAday 37 He J, et al. JAMA 1998;280:19305 75-150mg/TIAd (%) ( mg/d) 500 1500 14.5

17.2 (%) 19 3 160 325 11.5 14.8 26 3 75 150 10.9 15.2 32 6

<75 17.3 19.4 13 8 12.9 16.0 23 2 0 ATC Antithrombotic Trialists Collaboration. BMJ. 2002;324:71-86.

0.5 1.0 1.5 2.0 P<.0001 CAPRIE: RRR 14.9% p=0.045 * (%)

12 10 RRR 8.7% 10.2% 8.8% p=0.043 8 6 5.8% 5.3% 4

2 0 ASA CAPRIE (n=19,099) MI (n=4496) *MI, ; 1.6 1. Ringleb PA et al. Stroke 2004; 35: 528532. + Relative Risk (95% CI) Caneschi*

0.64 (0.15-2.72) Guiraud-Chaumeil 0.27 (0.03-2.37) AICLA 0.98 (0.50-1.91) ACCSG 0.83 (0.55-1.26) ESPS-2 0.74 (0.60-0.91) ESPRIT 0.79 (0.61-1.01)

Summary 0.77 (0.67-0.89) Favours aspirin + dipyridamole 0.01 * Data for stroke alone endpoint only 0.03 0.10 0.32 Favours aspirin 1.00 3.50

Risk Ratio (95% CI) Verro et al. Stroke 2008; 39: 13581363. ASA+ ASA+ PRoFESS 2 <=10 <72h 15.0 39.6%

6.6% 140 120 15.0 100 6.8% 80 28.3% 60 40.0% 28.8%

1.8% 1.8% ( lacune) 52.0% 52.1% 2.0% 2.1% n

TOAST ASA+ER -DP 10181 10151 40 20 PRoFESS <72h 121 (18%) ASA+ER- DP(n=672) P=0.006 75mg(n=688)mg(n=688) 86 (12.5%

) 36 ( ) 3 0 90 15.4% 15.6% PRoFESS 1360 <72h NIHSS=2.8 + (ASA+ER-DP)30 ASA+ER-DP ASA+ER-DP 36 3

1.Bath PMW, et al.Stroke.2010;41 4 :732-8 2. Sacco RL, et al. N Engl J Med. 2008;359:1238-1251 ASA+ 75mg/dmg/d % * * 25mg/d0 ICH 128

N Engl J Med, 2008 359:1238-1251 5%-85% Alberts MJ, et al. Stroke. 2004;35:175-178 1. ESSEN 2. 3.

Essen Essen 2010 73 Essen3 Essen<3 74 4.2% 95%CI 3.0%-5.5% 7.4% 95%CI 4.9%-9.8% P=0.001

Weimar C, et al. Stroke 2010;41(3):487-93 REACH:ESSEN ESSEN3 70% 14.0 12.0 /TIA %

10.0 8.0 ESSEN<3 30% 6.0 4.0 2.0 0.0 0 1 2 3 4

5 6 >6 ESSEN REACH 15,605 /TIATIA ( ) 1 ESSEN Christian Weimar, et al. The Essen Stroke Risk Score Predicts Recurrent Cardiovascular Events. Stroke, 2009, 40:350-354. ESSEN3 CAPRIE ESSEN 12 75mg

325mg 10 8 6 /TIA 4 (%) 2 0 0 1 2

3 4 5 6 ESSEN CAPRIE 6431 ESSEN >6 ( 96 1.4%) - Diener HC, et al. Clopidogrel for the secondary prevention of stroke. Expert Opin Pharmacother, 2005,6(5):755-764. ESSEN ESSEN3 <3

ESSEN /TIA 25mg(n=688) 23 20 20 % 15mg(n=688) 0.584) 14 AUC

0.571 (0.559- 0.575 (0.5640.586) 12 10 5mg(n=688) 0 ESSEN<3( ) ESSEN 3- 9mmol/L( ) NSAIDs

530 1 CYP2C19*2 CYP2C19 PPI PPI P450 CYP 2CY19 PPI

PPI Maximum Platelet Aggregation Intensity Induced by ADP 5 M, after M, after 5 Days of Clopidogrel Repeated Dosing (Mean SEM) 100 MAI(%) Induced by ADP 5 M 90 Treatment: Clopidogrel Alone Clopidogrel + Omeprazole 80 mg

80 70 Estimates of treatment difference (90% CI) = 8.00 (4.71 to 11.28) 60 50 40 30 20 10 0 D1 D2 Pre-dose Pre-dose D5 T2

Time (in Day) D5 T4 D5 T6 Mean inhibition of platelet aggregation (IPA) was diminished by 47% (24 hours) and 30% (Day 5) when Plavix and omeprazole were administered together Data on file FDA2010 10 New PPI , PPI PPI CYP2C19

PPI CYP2C19 1 * 1000 60.1

60 61.4 40 18.3 20 12.6 3.5 10

Coronary heart disease prevention: insights from modelling incremental cost effectiveness BMJ 327;1264 ESSEN

Recently Viewed Presentations

  • Best Practices in Defense Technology Development and ...

    Best Practices in Defense Technology Development and ...

    Best Practices in Defense Technology Development and Technology Maturity AssessmentsSystems & Software Technology Conference(SSTC)28 April 2010Mr. Jeffrey Craver Defense Acquisition UniversityLt Col Dian Hall DTRA-RD. 2010-04-28. DISTRIBUTION STATEMENT A. Approved for Public Release. Distribution Unlimited.
  • EMS Case Studies - desisales.com

    EMS Case Studies - desisales.com

    Simplified and streamlined deployment . due to preconfiguring each R.A.S.E.R. DX centrally and deploying remotely; Capital Expense savings, and environmentally sound in a harsh environment. Large American Cruise Line in need of remote site Data Center.
  • Engagement OBSERVE THE SAMPLE ROCKS AND CHOOSE ONE

    Engagement OBSERVE THE SAMPLE ROCKS AND CHOOSE ONE

    You have found two rocks. One is gray, lightweight, and has lot of holes throughout. The other is heavy and mad up of pieces of different colors. Are these most likely the same king of rock. Check Point Slide 22...
  • Web Search - Seattle University

    Web Search - Seattle University

    Web Search History (cont) In early 1994, Brian Pinkerton developed WebCrawler as a class project at U Wash. (eventually became part of Excite and AOL). A few months later, Fuzzy Maudlin, a grad student at CMU developed Lycos.
  • Unbridled Learning: What Everyone Should Know about P20

    Unbridled Learning: What Everyone Should Know about P20

    Attributes of standards based unit of study. Combined curriculum document. Core Content for Assessment. EPAS connected to College Readiness Standards. ELA deconstructed Standards. Kentucky Core Academic Standards. Kentucky Model Curriculum Framework. Math Deconstructed Standards . NGSS Science Standards. Curriculum Standards
  • Number the Stars Character & Chapter Summaries Annemarie

    Number the Stars Character & Chapter Summaries Annemarie

    Chapter 1 Summary. Annemarie Johansen and Ellen Rosen are ten years old. They are best friends and live in Copenhagen, Denmark. The story begins in 1943, and Germany has occupied Denmark for the past three years. All around Copenhagen, German...
  • MAGNETIC FORCES - Vula

    MAGNETIC FORCES - Vula

    Calculate the magnetic flux through a current loop. Use Lenz's law and Faraday's law to determine the direction and magnitude of induced emf's and currents. Explain the origin and speed of electromagnetic waves.
  • Chapter 8: The Asian World

    Chapter 8: The Asian World

    There, the emperor paid tribute to the sun goddess, Amaterasu, every year. According to legend, the first emperor was descended from the sun goddess. Shinto, however, did not satisfy the spiritual needs of all the Japanese people. ... Sui Yangdi...